Gerresheimer AG
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Uwe Ferdinand Röhrhoff
- Full Time Employees
- 13,528
- Sector
- Process industries
- Industry
- Containers/Packaging
- Address
- Peter-Müller-Straße 3 Dusseldorf NW Germany 40468
- IPO Date
- Jun 11, 2007
- Website
- gerresheimer.com
- Similar Companies
- Business
- Gerresheimer AG, along with its associated companies, develops, produces, and globally supplies specialized primary packaging and innovative drug administration systems. The company operates through its Plastics & Devices, Primary Packaging Glass, and Advanced Technologies divisions. The Plastics & Devices segment delivers sophisticated drug delivery systems, encompassing solutions like inhalers, insulin pens, auto-injectors, and prefillable plastic syringes for the pharmaceutical, biotech, diagnostics, and medical technology sectors. Additionally, it provides diverse containers and closures for solid, liquid, and ophthalmic applications, including PET bottles, eye droppers, nasal sprays, nebulizers, applicators, and various accessories, alongside prescription vials. This division also engages in contract manufacturing for complex medical devices. The Primary Packaging Glass division manufactures high-quality glass primary packaging for both the pharmaceutical and cosmetics industries. Its offerings include infusion, dropper, and syrup bottles, alongside injection vials, ampoules, and cartridges, often available in different glass types and colors such as clear, amber, or opal. The division further extends to miniature bottles and glass containers for liquid food, spices, and spirits, as well as specialized packaging for fragrances, deodorants, skincare, and wellness products. Recent innovations include Gx Elite vials, enhancing patient safety and manufacturing efficiency for sensitive drugs. The Advanced Technologies division is dedicated to pioneering smart drug delivery systems. This includes the development of micro pumps, digital platforms for therapeutic support, and wearable medication pumps designed for self-administration of critical medicines, catering to pharmaceutical and biotech partners. Recent advancements in this area include expanded collaboration on reusable autoinjector platforms and partnerships in connected adherence solutions. Founded in 1864, the company is headquartered in Düsseldorf, Germany. Gerresheimer maintains a global presence with over 40 production sites across Europe, the Americas, and Asia. The company is strategically focused on high-value solutions and sustainable growth, as evidenced by its validated CO2e reduction targets.
Company News
Gerresheimer AG (GRRMY) Q2 2026 Earnings Call Transcript
What Gerresheimer (GXI) Said on Its Q2 Earnings Call
Gerresheimer reports lower half-year core profit
Gerresheimer AG (GRRMY) Q1 2026 Earnings Call Transcript
Gerresheimer Q1 Earnings Call Highlights
Germany's Gerresheimer to sell two units to Apax for $1.71 billion including debt
Gerresheimer Q4 Earnings Call Highlights
Gerresheimer rejects takeover bid from US packing firm Silgan, say sources
Gerresheimer delays 2025 results release to June, stock to be removed from SDAX
Diamond Hill International Strategy Q4 2025 Portfolio Review
Gerresheimer appoints Uwe Röhrhoff as new interim CEO
Gerresheimer finds 2024 revenue-recognition issues after external probe
Gerresheimer AG (GRRMY) Q3 2025 Earnings Call Transcript
Gerresheimer's shares fall 11% after another outlook cut
Gerresheimer cuts 2025 outlook again as Q3 disappoints
Gerresheimer shares tank as financial regulator suspects accounting flaws
Activist investor wants review at Gerresheimer after taking stake
Gerresheimer shares rise on plan to sell moulded glass business
Gerresheimer calls a halt to discussions on potential takeover
Gerresheimer cuts its 2025 revenue outlook for second time